Top

Published in:

01-11-2016 | Original Article

MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition

Authors: Tana Machackova, Hana Mlcochova, Michal Stanik, Jan Dolezel, Michal Fedorko, Dalibor Pacik, Alexandr Poprach, Marek Svoboda, Ondrej Slaby

Published in: Tumor Biology | Issue 11/2016

Abstract

MicroRNAs (miRNAs) have been proven to be important oncogenes and tumor suppressors in wide range of cancers, including renal cell carcinoma (RCC). In our study, we evaluated miRNA-429 as potential diagnostic/prognostic biomarker in 172 clear cell RCC patients and as a potential regulator of epithelial-mesenchymal transition (EMT) in vitro. We demonstrated that miR-429 is down-regulated in tumor tissue samples (P < 0.0001) and is significantly associated with cancer metastasis (P < 0.0001), shorter disease-free (P = 0.0105), and overall survival (P = 0.0020). In addition, ectopic expression of miR-429 in 786-0 RCC cells followed by TGF-β treatment led to increase in the levels of E-cadherin expression (P < 0.0001) and suppression of cellular migration (P < 0.0001) in comparison to TGF-β-treated controls. Taken together, our findings suggest that miR-429 may serve as promising diagnostic and prognostic biomarker in RCC patients. We further suggest that miR-429 has a capacity to inhibit loss of E-cadherin in RCC cells undergoing EMT and consequently attenuate their motility.

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45.CrossRef

Ma X, Gao Y, Fan Y, Ni D, Zhang Y, Chen W, et al. Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PLoS One. 2013;8:1–12.CrossRef

KY X, Wu S. Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. Biomark Res. 2015;3:1–5.

Ohtsuka M, Ling H, Doki Y, Mori M, Calin G. MicroRNA processing and human cancer. J Clin Med. 2015;4:1651–67.CrossRefPubMedPubMedCentral

Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–71.CrossRefPubMed

Xu J, Yao Q, Hou Y, Xu M, Liu S, Yang L, et al. MiR-223/Ect2/p21 signaling regulates osteosarcoma cell cycle progression and proliferation. Biomed Pharmacother = Biomédecine Pharmacothérapie. 2013;67:381–6.CrossRefPubMed

Huang N, Wu Z, Lin L, Zhou M, Wang L, Ma H, et al. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget. 2015;6:15222–34.CrossRefPubMedPubMedCentral

Liu YC, Zhang M, Qian J, Bao M, Meng X, Zhang S, et al. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal transition by targeting KRAS in renal cell carcinoma cells. DNA Cell Biol. 2015;34:429–36.CrossRefPubMedPubMedCentral

Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283:14910–4.CrossRefPubMedPubMedCentral

10.

Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol. 2014;24:153–60.CrossRefPubMed

11.

Sundararajan BS, Gengenbacher N, Stemmler MP, Kleemann JA, Brabletz T. The ZEB1/miR-200c feedback loop regulates invasion via actin interacting proteins MYLK and TKS5. Oncotarget. 2015;6:27083–96.CrossRefPubMedPubMedCentral

12.

Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846–54.CrossRefPubMed

13.

Ceppi P, Mudduluru P, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010;8:1207–16.CrossRefPubMed

14.

Xiong H, Hong J, Du W, Lin Y, Ren L, Wang Y, et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem. 2012;287:5819–32.CrossRefPubMed

15.

Paul C. Renal cell carcinoma. Cancer Biomark. 2011;1–6:461–73.

16.

Stewart-Merrill SB, Thompson RH, Boorjian SA, Psutka SP, Lohse CM, Cheville JC, et al. Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol. 2015;33:4151–7.CrossRefPubMed

17.

Chan SH, Wang LH. Regulation of cancer metastasis by microRNAs. J Biomed Sci. 2015;22:9.CrossRefPubMedPubMedCentral

18.

Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, et al. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet. 2013;4:1–9.

19.

Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, et al. MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. 2014;390:19–30.CrossRefPubMedPubMedCentral

20.

Tang J, Li L, Huang W, Sui C, Yang Y, Lin X, et al. MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition. Cancer Lett. 2015;364:33–43.CrossRefPubMed

21.

Wang Y, Dong X, Hu B, Wang XJ, Wang Q, Wang WL, et al. The effects of Micro-429 on inhibition of cervical cancer cells through targeting ZEB1 and CRKL. Biomed Pharmacother. 2016;80:311–21.CrossRefPubMed

22.

Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z, et al. Downregulation of miR-429 and inhibition of cell migration and invasion in nasopharyngeal carcinoma. Mol Med Rep. 2016;13:3236–42.PubMed

23.

Zhu Q, He J, Chen D, Zhang B, Xu L, Ma H, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 2014;9:2.CrossRef

24.

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, et al. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget. 2016.

25.

Wu CL, Ho JY, Chou SC, Yu DS. MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 2014.

26.

Chen Y, Xiao Y, Ge W, Zhou K, Wen J, Yan W, et al. miR-200b inhibits TGF-β1-induced epithelial-mesenchymal transition and promotes growth of intestinal epithelial cells. Cell Death Dis. 2013;4:e541.CrossRefPubMedPubMedCentral

27.

Wu CL, Ho JY, Chou SC, Yu DS. MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 2016.

28.

Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, et al. miR-629 targets TRIM33 to promote TGFβ/Smad signaling and metastatic phenotypes in ccRCC. Mo Cancer Res. 2014;13:565–74.

29.

Huang W, Cen S, Kang X, Wang W, Wang Y, Chen X. TGF-β1-induced Fascin1 promotes cell invasion and metastasis of human 786-0 renal carcinoma cells. Acta Histochem. 2016;118:144–51.CrossRefPubMed

30.

Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-β promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin Shanghai. 2009;41:648–56.CrossRefPubMed

Title: MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition
Authors: Tana Machackova
Hana Mlcochova
Michal Stanik
Jan Dolezel
Michal Fedorko
Dalibor Pacik
Alexandr Poprach
Marek Svoboda
Ondrej Slaby
Publication date: 01-11-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5310-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis

Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma

The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression

Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis

miR-214 inhibits invasion and migration via downregulating GALNT7 in esophageal squamous cell cancer

Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer